{"altmetric_id":15745380,"counts":{"readers":{"mendeley":37,"citeulike":1,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4ea3cf058f61000257d","authors":["Kathleen M. Fox","Robert A. Gerber PharmD","Bjorn Bolinder","Jack Chen","Sanjaya Kumar"],"doi":"10.1016\/j.clinthera.2006.03.005","endpage":"395","first_seen_on":"2017-01-24T17:42:56+00:00","issns":["01492918"],"issue":"3","journal":"Clinical Therapeutics","last_mentioned_on":1369872000,"links":["http:\/\/dx.doi.org\/10.1016\/j.clinthera.2006.03.005"],"pmid":"16750453","pubdate":"2006-03-01T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"388","subjects":["drugtherapy"],"title":"Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000701","volume":"28","mendeley_url":"http:\/\/www.mendeley.com\/research\/prevalence-inadequate-glycemic-control-among-patients-type-2-diabetes-united-kingdom-general-practic"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7024934,"mean":6.263715082547,"rank":1647595,"this_scored_higher_than_pct":64,"this_scored_higher_than":4556798,"rank_type":"exact","sample_size":7024934,"percentile":64},"similar_age_3m":{"total_number_of_other_articles":88021,"mean":11.076774687571,"rank":26618,"this_scored_higher_than_pct":68,"this_scored_higher_than":59871,"rank_type":"exact","sample_size":88021,"percentile":68},"this_journal":{"total_number_of_other_articles":1427,"mean":3.3699242636746,"rank":235,"this_scored_higher_than_pct":71,"this_scored_higher_than":1027,"rank_type":"exact","sample_size":1427,"percentile":71},"similar_age_this_journal_3m":{"total_number_of_other_articles":7,"mean":2.1916666666667,"rank":2,"this_scored_higher_than_pct":71,"this_scored_higher_than":5,"rank_type":"exact","sample_size":7,"percentile":71}}},"demographics":{"users":{"mendeley":{"by_status":{"Librarian":1,"Researcher":5,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":8,"Student  > Postgraduate":3,"Other":5,"Student  > Master":6,"Student  > Bachelor":5,"Lecturer":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":30,"Social Sciences":1,"Psychology":2,"Agricultural and Biological Sciences":1,"Nursing and Health Professions":1,"Pharmacology, Toxicology and Pharmaceutical Science":1,"Arts and Humanities":1}}},"geo":{"mendeley":{"TZ":1,"GB":1,"ID":1}}},"posts":{"policy":[{"title":"Dapagliflozin in combination therapy for treating type\u00a02 diabetes: Diabetes (type 2) - dapagliflozin: evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA288\/documents\/diabetes-type-2-dapagliflozin-evaluation-report2","license":"public","citation_ids":[850871,2425188,1210031,1529860,15745378,15745380,15745381,15745383,694979,384459],"posted_on":"2013-05-30T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta288\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-d1e7d7e5d313ad08f7fb5256345480fc2cc443fa6804a21c6aff90574b7f4bc1.jpg"}}]}}